0001209191-22-003605.txt : 20220118
0001209191-22-003605.hdr.sgml : 20220118
20220118200216
ACCESSION NUMBER: 0001209191-22-003605
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220114
FILED AS OF DATE: 20220118
DATE AS OF CHANGE: 20220118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lager Joanne Jenkins
CENTRAL INDEX KEY: 0001816215
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 22536481
MAIL ADDRESS:
STREET 1: C/O ITEOS THERAPEUTICS, INC.
STREET 2: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iTeos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001808865
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 857-204-4583
MAIL ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-14
0
0001808865
iTeos Therapeutics, Inc.
ITOS
0001816215
Lager Joanne Jenkins
139 MAIN STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Medical Officer
Common Stock
2022-01-14
4
M
0
3500
4.30
A
3500
D
Common Stock
2022-01-14
4
S
0
2777
39.25
D
723
D
Common Stock
2022-01-14
4
S
0
723
39.58
D
0
D
Stock Option (Right to Buy)
4.30
2022-01-14
4
M
0
3500
0.00
D
2025-06-11
Common Stock
3500
185938
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.47 to $39.46, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.48 to $39.68, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
One-fourth of the shares subject to the stock option vested on April 1, 2020. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date
/s/ Adi Osovsky, as Attorney-in-Fact
2022-01-18